Use; Quality Control Sample Clauses

Use; Quality Control a. Neither party may alter the other party’s trademarks from the form provided and must comply with removal requests as to specific uses of its trademarks or logos.
Sample 1Sample 2Sample 3See All (378)
AutoNDA by SimpleDocs
Use; Quality Control a. Sourcewell must not alter Vendor’s Trademarks from the form provided by Vendor and must comply with Vendor’s removal requests as to specific uses of its trademarks or logos.
Sample 1Sample 2Sample 3See All (205)
Use; Quality Control. (a) Licensee agrees to maintain and preserve the quality of the Licensed Trademarks and to use, and to cause its Permitted Sublicensee to use, the Licensed Trademarks only in good faith and in a dignified manner consistent with such Licensee’s use of the Licensed Trademarks prior to the Effective Date and in accordance with the terms of this Agreement. In addition, Licensee shall ensure that all products and services provided by such Licensee and its Permitted Sublicensee under the Licensed Trademarks will be of sufficiently high quality to protect the Licensed Trademarks and the goodwill symbolized thereby. A Licensee shall not, and shall cause its Permitted Sublicensee not to, by any act or omission use or permit use of the Licensed Trademarks in any manner that tarnishes, degrades, disparages or reflects adversely on Licensor or its business or reputation or that would be detrimental to the Licensed Trademarks or their associated goodwill.
Sample 1
Use; Quality Control. 011723-JDC
Sample 1
Use; Quality Control. (i) Licensee agrees to maintain and preserve the quality of the Licensed Trademarks and to use, and to cause its permitted Sublicensees to use, the Licensed Trademarks only in good faith and in a dignified manner consistent with Licensor’s use of the Licensed Trademarks prior to the Effective Date and in accordance with the terms of this Agreement. In addition, Licensee shall ensure that all products and services provided by Licensee and its permitted Sublicensees under the Licensed Trademarks have been expressly authorized by Licensor in writing in each case and will be of sufficiently high quality to protect the Licensed Trademarks and the goodwill symbolized thereby. Licensee shall not, and shall cause its permitted Sublicensees not to, by any act or omission use or permit use of the Licensed Trademarks in any manner that tarnishes, degrades, disparages or reflects adversely on the Licensor or its reputation or that would be detrimental to the Licensed Trademarks or their associated goodwill.
Sample 1
Use; Quality Control. (a) Licensee agrees to maintain and preserve, and to require its Permitted Sublicensees to maintain and preserve, the quality of the Licensed Materials and to use, and to cause its Permitted Sublicensees to use, the Licensed Materials only in good faith and in a dignified manner and in accordance with the terms of this Agreement. In addition, Licensee shall ensure that all products and services provided by Licensee and its Permitted Sublicensees under the Licensed Materials will be of sufficiently high quality to protect the Licensed Materials and the goodwill symbolized thereby. For purposes of this Agreement, the terms “dignified manner” and “sufficiently high quality” shall be intended to mean the same or better dignity of use and quality expressed by Licensor in its own use of its trademarks and trade names including, but not limited to the Licensed Materials, as determined in the sole reasonable discretion of Licensor. Licensee shall not, and shall cause its Permitted Sublicensees not to, by any act or omission, use or permit use of the Licensed Materials in any manner that tarnishes, degrades, disparages or reflects adversely on Licensor, its reputation, or in a manner that would be detrimental to the Licensed Materials or their associated goodwill.
Sample 1

Related to Use; Quality Control

  • Quality Control A. Controlled Affiliate agrees to use the Licensed Marks and Name only in connection with the licensed services and further agrees to be bound by the conditions regarding quality control shown in attached Exhibit A as they may be amended by BCBSA from time-to-time.

  • Product Quality 4.1 The following provisions shall apply to Product after Production:

  • Money Market Fund Compliance Testing and Reporting Services Subject to the authorization and direction of the Trust and, in each case where appropriate, the review and comment by the Trust’s independent accountants and legal counsel, and in accordance with procedures that may be established from time to time between the Trust and the Administrator, the Administrator will:

  • Clinical Data and Regulatory Compliance The preclinical tests and clinical trials conducted or sponsored by the Company (collectively, “studies”) that are described in, or the results of which are referred to in, the Registration Statement, the Time of Sale Prospectus or the Prospectus were and, if still pending, are, to the Company’s knowledge, being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures; each description of the results of such studies is reasonably accurate and complete in all material respects in the context of the experimental set-up and fairly presents the data derived from such studies within the limits of interpretation by people trained in the trade, and the Company and its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement, the Time of Sale Prospectus or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the “Regulatory Agencies”) for the operation of the Company’s business as currently conducted, except as could not be expected, individually or in the aggregate, to have a Material Adverse Effect; neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are described or referred to in the Registration Statement, the Time of Sale Prospectus or the Prospectus; and the Company and its subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules and regulations of the Regulatory Agencies, except as could not be expected, individually or in the aggregate, to have a Material Adverse Effect.

  • Data Access Services State Street agrees to make available to the Fund the Data Access Services subject to the terms and conditions of this Addendum and such data access operating standards and procedures as may be issued by State Street from time to time. The Fund shall be able to access the System to (i) originate electronic instructions to State Street in order to (a) effect the transfer or movement of cash or securities held under custody by State Street or (b) transmit accounting or other information (the transactions described in (i)(a) and (i)(b) above are referred to herein as “Client Originated Electronic Financial Instructions”), and (ii) access data for the purpose of reporting and analysis, which shall all be deemed to be Data Access Services for purposes of this Addendum.

Time is Money Join Law Insider Premium to draft better contracts faster.